Cite

    Haijun Qu et al.. “Pharmacokinetic, metabolic stability, plasma protein binding and CYP450s inhibition/induction assessment studies of N-(2-pyridylmethyl)-2-hydroxiymethyl-1-pyrrolidinyl-4-(3-chloro-4-methoxy-benzylamino)-5-pyrimidine-carboxamide as potential type 5 phosphodiesterase inhibitors.” Animal cells and systems, vol. 23, no. 3, 2019, pp. 155–163. http://access.bl.uk/ark:/81055/vdc_100086188614.0x000009